SARS COV Antigen Testing

This test uses advanced immunofluorescence-based lateral flow technology in a sandwich design for qualitative detection of nucleocapsid protein from SARS-COV-2. This test provides an automated and objective result in less than an hour. This is under FDA Emergency Use Authorization. For further information about our SARS-COV-2 Antigen Testing, please go to the following links:

Healthcare Provider Fact Sheet
Patient Fact Sheet
FDA Emergency Use Authorization Information

SARS COV 2 Molecular Testing

This test is a rapid molecular test utilizing an isothermal nucleic acid amplification technology intended for the qualitative detection of nucleic acid from the SARS-COV-2 Virus. This test provides an automated and objective result in less than an hour. This test is under FDA Emergency Use Authorization. For further information about our SARS-COV-2 Molecular testing, please go to the following links:

Healthcare Provider Fact Sheet
Patient Fact Sheet
FDA Emergency Use Authorization Information

Note: The Laboratory will continue to report results to the local and state health department.